Camurus ABCAMRF +12.98%83 5-Year ROIIC % is 259.92 as of Dec. 2025. GuruFocus rates CAMRF with a GF Score™ of 83/100 and a GF Value™ of $69.05 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,178 Biotechnology companies, Camurus AB ranks better than 89.73% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Camurus AB's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was 259.92%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Camurus AB's 5-Year ROIIC % or its related term are showing as below:
CAMRF's 5-Year ROIIC % is ranked better than 89.73% of 1178
companies
in the Biotechnology industry
Industry Median: -11.255
vs CAMRF: 259.92
Camurus AB (OTCPK:CAMRF) 5-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Camurus AB 5-Year ROIIC % Related Terms
Camurus AB 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Camurus AB's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, ALNY: 5-Year ROIIC % Comparison
For the Biotechnology subindustry, Camurus AB's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB 5-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Camurus AB's 5-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Camurus AB (CAMRF) has a 5-Year ROIIC % of 259.92 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Camurus AB and its competitors. According to the industry distribution chart, Camurus AB ranks #121 out of 1178 companies in the Biotechnology industry, placing it in the top 10.3%.
Is Camurus AB's 5-Year ROIIC % too high?
Camurus AB's current 5-Year ROIIC % is 259.92. Based on the distribution chart, Camurus AB ranks #121 out of 1178 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's 5-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #121 out of 1178 companies for 5-Year ROIIC %. This places Camurus AB in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Biotechnology company?
A good 5-Year ROIIC % depends on the Biotechnology industry context. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Camurus AB and its competitors. Camurus AB's current 5-Year ROIIC % is 259.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $69.05, compared to a current price of $61.01 — trading 11.6% below its estimated fair value. The current 5-Year ROIIC % is 259.92. Camurus AB's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Camurus AB (CAMRF), the current 5-Year ROIIC % is 259.92 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $61.01 is trading 11.6% below its estimated GF Value™ of $69.05.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
5-Year ROIIC %: 259.92
GF Value™: $69.05 vs. price of $61.01 (11.6% below fair value)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
83GF Score
Get the complete analysis for CAMRF
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
